Bristol-Myers’ $74B Celgene buy wins antitrust nod in FTC party-line split vote
admin 18th November 2019 Uncategorised 0Industry watchers largely expected that Bristol-Myers Squibb and Celgene would win U.S. antitrust clearance for their $74 billion merger. But what’s perhaps unexpected is that the permission was not unanimous, spelling an ill omen for future large biopharma deals should Democrats move into the White House.
More: Bristol-Myers’ B Celgene buy wins antitrust nod in FTC party-line split vote
Source: fierce